NextGenNK is a Competence Center for the development of next generation NK cell-based cancer immunotherapies. The Center is coordinated by Karolinska Institutet and collaborates with the Karolinska University Hospital and prominent national and international industrial partners. The Center was launched in 2020, and is jointly funded by Vinnova, KI, and the Industrial partners.
XNK receives certificate of GMP compliance of a manufacturer from the Medical Products Agency
XNK Therapeutics has received a GMP manufacturing license and a certificate of GMP compliance from the Swedish Medical Products Agency.
Article: Industry appetite for natural killer cells intensifies
Interest in NK cells has escalated and companies start collaborations to bring NK-driven programs and tools into their portfolios. The article in nature biotechnology highlights NK cell products, NK cell-directed antibodies and companies associated to NK cell therapies. Article by Cormac Sheridan in nature biotechnology Feb 2023.
Article: NK cells are promising in cancer treatment
Jon Tsai, Medical Lead Sanofi Sweden and NextGenNK's director Hans-Gustaf Ljunggren were interviewed by the Swedish industry magazine "Framtidens Läkemedel". They discussed the importance of collaborations, NK cells, immuno-oncology and NextGenNK. (Article in Swedish). Photo: Gonzalo Irigoyen
Awards and recognitions
NextGenNK at Innate Killer Summit 2023
co-leader Evren Alici was selected as one of the world-class speakers at Innate Killer Summit 2023.
Arnika Wagner - KID funding
Arnika Wagner, assistant professor at Karolinska Institutet, was granted KID funding for a new PhD student.
Nutsa Burduli - Best Oral Presentation
Nutsa Burduli, PhD student at Karolinska Institutet was awarded Best Oral Presentation at Tissue & Motion Conference 2022, Djurönäset, Sweden.
Adaptive single-KIR+NKG2C+ NK cells expanded from select superdonors show potent missing-self reactivity and efficiently control HLA-mismatched acute myeloid leukemia
Haroun-Izquierdo A. et al, J Immunother Cancer, 2022
Generation of NK cells with chimeric-switch receptors to overcome PD1-mediated inhibition in cancer immunotherapy
Susek KH et al, Cancer Immunol Immunother, 2022
A tractable microscopy- and flow cytometry-based method to measure natural killer cell-mediated killing and infiltration of tumor spheroids
Schwietzer et al, Methods in Cell Biology, 2022